We serve Chemical Name:3-(Bromomethyl)pyridine hydrobromide CAS:4916-55-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(Bromomethyl)pyridine hydrobromide
CAS.NO:4916-55-6
Synonyms:3-Picolyl Bromide Hydrobromide;3-(BroMoMethyl)pyridine HydrobroMide;3-(bromomethyl)pyridine,hydrobromide;3-Bromomethyl-pyridine;3-(Bromomethyl)pyridine;MFCD01321314;Pyridine, 3-(bromomethyl)-, hydrobromide (1:1);3-(Bromomethyl)pyridine hydrobromide (1:1)
Molecular Formula:C6H7Br2N
Molecular Weight:252.934
HS Code:2933399090
Physical and Chemical Properties:
Melting point:150-155ºC(lit.)
Boiling point:265.2ºC at 760 mmHg
Density:N/A
Index of Refraction:
PSA:12.89000
Exact Mass:250.894516
LogP:2.93460
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3261 8/PG 2
Packing Group:Ⅱ
Contact us for information like 3-Picolyl Bromide Hydrobromide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(Bromomethyl)pyridine hydrobromide (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(Bromomethyl)pyridine Use and application,MFCD01321314 technical grade,usp/ep/jp grade.
Related News: Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance. 3-(Bromomethyl)pyridine hydrobromide manufacturer Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. 3-(Bromomethyl)pyridine hydrobromide supplier Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. 3-(Bromomethyl)pyridine hydrobromide vendor From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend. 3-(Bromomethyl)pyridine hydrobromide factory At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival.
